Results 51 to 60 of about 398,944 (237)

Lack of mortality in 22 children with sickle cell anemia and severe malarial anemia [PDF]

, 2017
Retrospective studies suggest that there is high mortality in children with sickle cell anemia (SCA) and severe malaria. We assessed mortality in Ugandan children with severe malarial anemia (SMA, n = 232) or cerebral malaria (CM, n = 267) by sickle cell
Bangirana, Paul, Idro, Richard, John, Chandy C., Namazzi, Ruth, Opoka, Robert O., Shabani, Estela   +5 more
core   +1 more source

Studies on the Hemoglobin of Cooley's Anemia and Cooley's Trait [PDF]

, 1952
The diseases sickle cell anemia and Cooley's anemia (also known as thalassemia or Mediterranean anemia) have associated with them "minor" or "trait" forms of the disease in which the symptomatology is minimal, and the abnormalities in the red cells are ...
Rich, Alexander
core  

Exertional sickling: Questions and controversy [PDF]

, 2014
Sickle cell trait (SCT) occurs in about 8% of African-Americans and is often described to be of little clinical consequence. Over time, a number of risks have emerged, and among these are rare but catastrophic episodes of sudden death in athletes and ...
Blinder, Morey A., Russel, Sarah
core   +3 more sources

The Virginia Sickle Cell Anemia Awareness Program: Education, Screening, and Counseling [PDF]

, 1977
In 1968, a program of screening for sickle trait carriers was begun as part of the work of the Hematology Division, Department of Medicine, at the Medical College of Virginia.
Cooper, Florence N., Scott, Robert B.
core   +1 more source

Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β‐Thalassemia

Advanced Science, EarlyView.
Context of Research: β‐thalassemia affects millions worldwide. DNMT inhibitors are effective HbF‐inducers that benefit patients with β‐thalassemia. Existing DNMT inhibitors are not approved for β‐thalassemia treatment due to dose‐limiting toxicity.What We Find: DMT207 traps DNMT1 into helix‐kinked inactive conformation and enhances its interaction with
Yijie Shen, Jiale Wei, Shibing Tang, Dongliang Wu, Liangyi Zong, Shuyuan Ma, Qing Xiong, Ruijie Gong, Siyuan Xu, Chuxuan Peng, Qin Feng, Songchen Liu, Qitong Liu, Yuhua Ye, Quan Zhao, Cheng Luo, Peng Huang, Zhihai Li, Xiangqian Kong, Xianjiang Lan   +19 more
wiley   +1 more source

Pulmonary hypertension in adolescents with sickle cell disease [PDF]

, 2016
Sickle cell disease consists of a group of disorders that have a similar mutation in at least one of the beta-globin chains of hemoglobin. This results in a change of the hemoglobin to sickle shaped cells when in the deoxygenated state.
Akinyemi, Katherine
core   +1 more source

Expression of Regulatory Platelet MicroRNAs in Patients with Sickle Cell Disease [PDF]

, 2013
Background: Increased platelet activation in sickle cell disease (SCD) contributes to a state of hypercoagulability and confers a risk of thromboembolic complications.
A Abdollahi, A Dixon-McIver, A Osman, A Schedel, A Smolenski, A Tomer, AA Kondkar, AD Blann, AI Badeaux, AJ Saldanha, AM Healy, BM Steele, Claudia Coronnello, D Betel, D Betel, DA Hosack, DP Bartel, DV Gnatenko, EM Novelli, ER Popescu, G Bazzoni, Gregory J. Kato, Guoying Yu, H Bruchova, H Seitz, HA Brittain, I Hers, I Toma, J Villagra, Jen-Tsan Ashley Chi, JF Noronha, JS Mohan, K Joop, K Kaushansky, K Konishi, Kimberly Woodhouse, LL Horstman, LR Queen, M Kannan, M Kertesz, Maria G. Kapetanaki, Mark T. Gladwin, MC Ammons, ML Freedman, ML Jison, MP Hunter, N Chavda, N Raghavachari, Naftali Kaminski, Nalini Raghavachari, P Landry, Panayiotis V. Benos, PV Browne, R Antonucci, R Garzon, R Ross, R Visone, RC Friedman, RJ Berckmans, RL Nachman, RT Schermuly, S Amisten, S Kim, S Masaki, S Mendjan, S Nagalla, Shilpa Jain, SP Lee, Suchitra Barge, T Wun, V Ambros, W Huang da   +71 more
core   +3 more sources

Proteomic Analysis of Golden Sputum Reveals Pulmonary Complement Activation During Acute Chest Syndrome in Children With Sickle Cell Disease

American Journal of Hematology, EarlyView.
ABSTRACT Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited.
Slimane Allali, Nabiha Sbeih, Rachel Rignault‐Bricard, Johanna Bruce, Morgane Le Gall, Claire Heilbronner, Noemie de Cacqueray, Sofia Angyalosy, Melissa Taylor, Joséphine Brice, Mariane de Montalembert, Martina Bevacqua, Emilie‐Fleur Gautier, Olivier Hermine, Thiago Trovati Maciel   +14 more
wiley   +1 more source

The Fabulous Impact of CRISPR Method in Sickle Cell Disease Treatment

Trends in Peptide and Protein Sciences, 2021
Sickle cell diseases are the most prevalent monogenic blood diseases with complications such as severe end-organ harm, pain, and reduced life expectancy. Dealing options for sickle cell diseases are inadequate, as there are just two FDA-approved drugs to
Vida Ebrahimi, Atieh Hashemi
doaj   +1 more source

Synthesis and Screen of a Proline-Rich Combinatorial Library Towards the Identification of Sickle Cell Hemoglobin Polymerization Inhibitors [PDF]

, 2015
Sickle cell disease is a genetic disorder that affects the hemoglobin within red blood cells. A point mutation in the gene coding for the β-subunit of hemoglobin allows the mutant chain to interact with a hydrophobic pocket of another hemoglobin in a ...
Steenberge, Laura
core   +1 more source